Drug-Induced Linear IgA Dermatosis: Next Management Step When Discontinuing the Causative Medication Was Not Enough

Clinical Scenario

Drug-induced linear IgA dermatosis (DILAD) is a form of linear IgA bullous dermatosis triggered by a causative medication. Discontinuation of the offending drug is the initial management step and may produce remission. However, in some patients the disease does not adequately respond to withdrawal alone, and further intervention is required.

Prior Treatment — Goals Not Achieved

The first-line approach — discontinuation of the offending medication — targets cessation of new lesion formation within 1–3 days and full resolution of existing skin lesions within 2–7 weeks. When these goals are not met and the condition persists or progresses, escalation to additional therapy is indicated.

Next-Step Treatment Approach

For serious or persistent DILAD not controlled by drug withdrawal, additional pharmacological therapy becomes necessary. The protocol draws on agents from multiple therapeutic classes. Which options apply, and how they are combined or sequenced, is detailed in the full structured regimen.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jdv.19880Digital

Discontinuation of the offending medication may produce remission of DILAD.

In serious and persistent cases, additional therapy with dapsone, systemic corticosteroids (prednisone or prednisolone) 0.5 mg/kg to 1 mg/kg/ day and/or topical glucocorticoids, colchicine or IVIG may be required to stop progression of the disease.

View source ↗